Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 8/20 | 0.33 |
| ▸ | JAK2 | O60674 | 6/20 | 0.33 |
| ▸ | JAK1 | P23458 | 5/20 | 0.33 |
| ▸ | TYK2 | P29597 | 3/20 | 0.33 |
| ▸ | PKN2 | Q16513 | 1/20 | 0.32 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.32 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.31 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1851197 | 0.79 | JAK3 (0.56) | JAK3JAK2JAK1TYK2 | |
| SCHEMBL1850260 | 0.76 | IRAK4 (0.40) | JAK3IRAK4MAPK10 | |
| SCHEMBL1853474 | 0.74 | JAK3 (0.34) | JAK3JAK2JAK1TYK2PKN2 | |
| SCHEMBL12395134 | 0.57 | STAT3 (0.48) | JAK3JAK2JAK1TYK2 | |
| SCHEMBL2148393 | 0.57 | IRAK4 (0.38) | JAK3JAK2JAK1TYK2PKN2 | |
| SCHEMBL4062262 | 0.56 | JAK3 (0.65) | JAK3JAK2JAK1TYK2PKN2 | |
| SCHEMBL1396029 | 0.56 | KDM4E (0.40) | AURKB | |
| SCHEMBL19153750 | 0.56 | ADORA3 (0.38) | AURKB | |
| Hydrochloric Acid SCHEMBL15754750 | 0.54 | HRH4 (0.43) | IRAK4 | |
| SCHEMBL400666 | 0.53 | ADORA3 (0.38) | AURKBIRAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110165183-A1 | PIPERIDINE DERIVATIVES AS JAK3 INHIBITORS | BIOCRYST PHARMACEUTICALS, INC. (US) | 2011-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110165183-A1 | PIPERIDINE DERIVATIVES AS JAK3 INHIBITORS | JAK3, JAK2, JAK1 | JAK3 1/4885JAK2 2/4885JAK1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.